Relating to warning labels for opioid prescription drugs.
Summary
SB 1986 would require opioid prescription drugs dispensed in Texas to carry a warning label on the bottle or container stating that opioids are addictive and can cause respiratory depression and overdose. The bill directs the Texas State Board of Pharmacy to adopt rules specifying the label language, with the required warning substantially similar to: “CAUTION: Opioid. Risk of Addiction, Respiratory Depression, and Overdose.”
The measure amends the Health and Safety Code provisions governing pharmacist conduct and controlled substance dispensing. It would make it unlawful for a pharmacist to dispense an opioid unless the container bears the required warning label, and it adds a new rulemaking mandate for the Pharmacy Board under Section 481.0761. The bill applies only to opioid prescriptions dispensed on or after March 1, 2026, and it authorizes either immediate effect upon a two-thirds vote or a default effective date of September 1, 2025.
Impact
SB 1986 would change Texas pharmacy law by adding a new dispensing requirement for opioids and by expanding the statutory duties of the Texas State Board of Pharmacy to adopt implementing rules. Pharmacies and pharmacists would need to ensure opioid containers are labeled with the mandated warning before dispensing, while prescriptions filled before March 1, 2026, would remain governed by prior law. The bill primarily affects pharmacists, pharmacies, the Pharmacy Board, and patients receiving opioid prescriptions.
Sentiment
The available context suggests the bill moved through the legislative process without recorded opposition in the provided vote history, and there are no committee transcript excerpts indicating debate. Its subject matter and straightforward consumer-warning approach suggest a generally public-health-oriented posture focused on opioid safety and overdose prevention. The bill was advanced to the House General State Calendar, indicating it received sufficient support to continue moving forward.
Contention
No specific points of contention are documented in the provided materials. Potential areas of concern, based on the bill text, could include the administrative burden on pharmacies, the cost and logistics of relabeling opioid containers, and whether the warning language is sufficiently clear or standardized. However, no named opponents, amendments, or disputed issues are reflected in the supplied discussion or voting history.